Program Year 2018
General Payments631,243 providers 1,630 companies
Dataset totals — PY2018
$2,269,563,457.16
- Category: General Payments
- Program year: 2018
- Records: 10,888,595
- Providers: 631,243
- Reporting companies: 1,630
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- Dataset-level totals for the labeled program year, General Payments only. Research and Ownership/Investment are separate datasets and are never combined into these figures.
- Methodology & Data — sourcing, labeling, and limitations.
Coverage: program years 2018–2024 are loaded, General Payments only. This page reflects the CMS publication snapshot for PY2018.
Reported totals by company — PY2018 (20 shown)
Sorted by reported total — a dataset fact, not a ranking of conduct.
| Company | Reported | Records | Providers |
|---|---|---|---|
| Stryker Corporation | $78,062,274.11 | 107,179 | 22,327 |
| Zimmer Biomet Holdings, Inc. | $72,615,575.70 | 86,208 | 24,120 |
| BOSTON SCIENTIFIC CORPORATION | $72,337,417.89 | 144,398 | 39,557 |
| Arthrex, Inc. | $70,206,196.16 | 19,748 | 3,483 |
| Allergan Inc. | $67,854,029.11 | 413,852 | 96,498 |
| Medtronic USA, Inc. | $65,504,481.10 | 95,961 | 21,752 |
| DePuy Synthes Products LLC | $61,393,577.86 | 2,511 | 409 |
| Acerta Pharma LLC | $41,281,093.88 | 456,106 | 84,572 |
| ABBVIE INC. | $40,543,805.56 | 327,078 | 64,085 |
| PFIZER INC. | $39,441,141.35 | 594,653 | 113,790 |
| Amgen Inc. | $38,436,527.20 | 401,405 | 82,367 |
| Medtronic Vascular, Inc. | $36,883,773.40 | 148,737 | 24,228 |
| Merck Sharp & Dohme Corporation | $35,827,448.80 | 289,345 | 85,425 |
| Medical Device Business Services, Inc. | $35,664,812.53 | 34,058 | 7,255 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $34,870,926.37 | 337,826 | 73,848 |
| INTUITIVE SURGICAL, INC. | $33,540,136.17 | 85,048 | 10,424 |
| GENZYME CORPORATION | $29,692,235.46 | 71,048 | 16,952 |
| Smith & Nephew, Inc. | $29,028,544.71 | 59,239 | 17,321 |
| Carl Zeiss Meditec, Inc. | $28,606,440.07 | 4,866 | 2,721 |
| Janssen Pharmaceuticals, Inc | $28,130,511.35 | 346,015 | 71,802 |
Reported totals by specialty — PY2018 (20 shown)
Sorted by reported total.
Other program years
Natures of payment
- Royalty or License
- Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
- Consulting Fee
- Food and Beverage
- Acquisitions
- Travel and Lodging
- Education
- Honoraria
- Current or prospective ownership or investment interest
- Grant
- Compensation for serving as faculty or as a speaker for a medical education program
- Gift
- Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program
- Debt forgiveness
- Long term medical supply or device loan
- Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program
- Charitable Contribution
- Entertainment